Novartis pauses screening and treatment across rapcabtagene trials
Novartis temporarily pausing screening, randomization and treatment across rapcabtagene autoleucel trials in autoimmune diseases.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.